Last reviewed · How we verify
Q8003
Q8003 is a selective inhibitor of the kappa opioid receptor.
Q8003 is a selective inhibitor of the kappa opioid receptor. Used for Opioid use disorder.
At a glance
| Generic name | Q8003 |
|---|---|
| Sponsor | QRxPharma Inc. |
| Drug class | kappa opioid receptor antagonist |
| Target | kappa opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
By selectively inhibiting the kappa opioid receptor, Q8003 aims to reduce the dysphoric effects associated with kappa opioid receptor activation, which are thought to contribute to the development of opioid use disorder. This mechanism is distinct from traditional opioid receptor agonists, which activate the mu opioid receptor and can lead to euphoria and dependence.
Approved indications
- Opioid use disorder
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Pharmacokinetics of Morphine and Oxycodone in Frail Elderly Undergoing Cardiac Surgery
- Post Operative Pain Control After Pediatric Hip Surgery (NA)
- Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer (NA)
- Neurotoxic Adverse Effects of Morphine and Oxycodone for Pain in Terminal Patients With Diminished Renal Function (PHASE4)
- Visceral Pain From the Upper Urinary Tract - a Trial on the Effect of Morphine and Oxycodone in Patients Undergoing PCNL (PHASE3)
- Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients (PHASE2)
- Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty (PHASE2)
- Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Q8003 CI brief — competitive landscape report
- Q8003 updates RSS · CI watch RSS
- QRxPharma Inc. portfolio CI